Disability as an outcome in MS clinical trials.
BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials. Preventing progressive disability is the key therapeutic goal but there remains no validated definition for its measurement in a trial context. M...
Hlavní autoři: | Ebers, G, Heigenhauser, L, Daumer, M, Lederer, C, Noseworthy, J |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2008
|
Podobné jednotky
-
Measuring disability progression in MS
Autor: Ebers, G, a další
Vydáno: (2005) -
Combined MRI lesions and relapses as a surrogate for disability in MS.
Autor: Ebers, G, a další
Vydáno: (2012) -
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.
Autor: Noseworthy, J, a další
Vydáno: (1990) -
Natural history of MS.
Autor: Ebers, G, a další
Vydáno: (2008) -
Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS.
Autor: Ebers, G, a další
Vydáno: (2011)